UV-C Phototherapy · Drug-Free

Photohemo
Irradiation Treatment

Light as medicine. Precision without drugs.

PHIT harnesses the selective power of pulsed UV-C irradiation to target cancer cells — exploiting the biological difference between tumor and healthy tissue at the cellular level.

Understand the Process Read the Science

Procedure

How PHIT Works

A four-step extracorporeal process — blood leaves the body, is exposed to controlled UV irradiation, and returns activated and treated.

Blood Withdrawal

A small volume of the patient's blood is carefully drawn through a butterfly needle and collected into an anticoagulant solution to prevent clotting during treatment.

UV Irradiation Chamber

Blood flows through a quartz glass irradiation chamber, where it is exposed to controlled UV-C energy (230–280 nm) generated by a xenon lamp — irradiated a second time as it returns for optimal results.

Photolysis & Activation

UV light breaks down proteins and pathogens in the blood through photolysis. Reactive oxygen species (ROS) are generated, initiating targeted cell death in cancer and pathogen cells while healthy cells self-repair.

Reinfusion

Treated blood is reinfused into the patient's bloodstream in a closed circuit system. The entire procedure typically takes 30–45 minutes and can be performed on an outpatient basis.

Mechanism

The Science Behind PHIT

Grounded in decades of photobiology research — the selectivity of PHIT is rooted in fundamental differences between cancer and healthy cells.

UV Therapeutic Spectrum

200nm UV-C280nm UV-C400nm Visible

▲ PHIT TARGET RANGE: 230–280nm UV-C

⬡

FAS/CD95 Receptor SelectivityCancer cells carry significantly more FAS (CD95) receptor domains on their surface than healthy cells — making them far more susceptible to UV-induced apoptosis.
◈

Reactive Oxygen Species (ROS)Pulsed UV irradiation stimulates ROS and hydroxyl radical (OH) production that overwhelms cancer cells' oxidative stress removal function — triggering cell death only in tumor cells at therapeutic doses.
✦

Healthy Cell RepairNon-tumor cells successfully repair the UV-induced DNA damage using endogenous repair enzymes — surviving the same irradiation dosage that destroys cancer cells.
◎

Immune ActivationPhotolysis generates autologous antigens from the patient's own blood, priming the immune system to identify and attack residual cancer cells throughout the body.

Xenon Lamp Technology

Quartz Discharge

A quartz discharge xenon lamp generates broad-spectrum UV-C pulses tens of thousands of times more intense than conventional UV lamps — enabling the pulsed photon therapy mechanism.

Target Wavelength

230–280 nm UV-C

The UV-C therapeutic range is precisely tuned to exploit differential FAS/CD95 receptor density between cancer and healthy cells, maximizing selectivity and minimizing collateral damage.

Peer-Reviewed Research

Published 2022

Results published in Frontiers in Bioscience (Schol.) demonstrate selective cancer cell death at low UV doses while non-tumor cells survive identical irradiation.

→ View on PubMed (PMID 36575836)

Treatment Duration

30–45 Minutes

Outpatient procedure. Blood is irradiated twice — once outbound and once on return — in a fully closed circuit system for optimum photolytic effect.

Clinical Benefits

Why Patients
Choose PHIT

UV blood irradiation therapy provides a spectrum of documented physiological effects beyond direct cancer cell targeting.

◎

Drug-Free

No photosensitizing agents or pharmaceutical compounds required. PHIT achieves its therapeutic effect through light physics alone — zero chemical side effects.

⟁

Selective Targeting

Cancer cells' elevated FAS receptor density makes them preferentially susceptible to UV-induced apoptosis at doses that leave healthy tissue intact and self-repairing.

✦

Immune Enhancement

Photolysis activates autologous antigen production, strengthening the body's natural immune surveillance and response against remaining cancer cells.

◈

Anti-Microbial

UV irradiation inactivates bacteria, viruses, and fungi in the blood — reducing total pathogen load and supporting overall immune function concurrently.

⬡

Improved Circulation

Documented increases in venous oxygen, enhanced microcirculation, and improved tissue oxygenation — supporting overall cardiovascular health and treatment recovery.

▲

Complementary Therapy

Can be used alongside conventional treatments. UBI has been administered as adjunctive cancer therapy in Germany and used in combination with chemotherapy and radiation.

Historical Context

A Century of
Phototherapy

UV blood irradiation has a deep scientific lineage — from Nobel Prize-winning discoveries to FDA-approved oncology treatments.

1890s

Finsen's Discovery

Niels Ryberg Finsen documented the curative properties of concentrated light radiation on skin conditions, reporting a 98% success rate with lupus vulgaris. He is considered the founding father of UV phototherapy.

Nobel Prize in Medicine — 1903

1928

The Knott Hemo-Irradiator

Dr. Emmet Knott of Seattle developed the first extracorporeal UV blood irradiation device, receiving a US patent for "Means for Treating Blood-Stream Infection." Used through the 1950s for bacterial sepsis, viral infections, and pneumonia.

US Patent Granted

1950s

Early Clinical Use

Extensive clinical use for tuberculosis, arthritis, poliomyelitis, rheumatoid arthritis, and cancer. Dr. Josef M. Issels in Europe integrated UBI into comprehensive cancer immunotherapy programs for thousands of patients.

Mainstream Clinical Use

1987

FDA Approval — Extracorporeal Photopheresis

Yale's Dr. Richard Edelson developed a photopheresis machine for T-cell lymphoma. The FDA approved Extracorporeal Photopheresis (ECP) — an advanced form of blood irradiation — for cutaneous T-cell lymphoma (CTCL).

FDA Approved for CTCL

2022

Pulsed UV Irradiation Breakthrough

Peer-reviewed research published in Frontiers in Bioscience demonstrated that pulsed UV-C irradiation (230–280 nm) selectively kills cancer cells via FAS/CD95 receptor overexpression and ROS generation, while healthy cells self-repair — establishing the scientific foundation for next-generation drug-free PHIT devices.

Peer-Reviewed · PubMed PMID 36575836

Medical Disclaimer: The information on this website is provided for educational and informational purposes only and does not constitute medical advice. PHIT and UV blood irradiation therapy are investigational or complementary modalities. Consult a licensed healthcare professional before undertaking any medical treatment. Results may vary. References to research do not constitute FDA endorsement of PHIT devices unless explicitly stated.

PhotohemoIrradiation Treatment